nach oben

Erschienen in:

01.12.2023 | Original Article

Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition

verfasst von: Ryo Sueyoshi, Nanami Furuhashi, Junya Ishii, Ryusuke Yamaguchi, Marumi Kawakami, Kenji Tanabe, Osamu Segawa

Erschienen in: Pediatric Surgery International | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Total parenteral nutrition causes liver damage in patients with short bowel syndrome (SBS), in whom intestinal failure-associated liver disease (IFALD) is the strongest risk factor for mortality. We previously demonstrated the efficacy of dipeptidyl peptidase-4 inhibitors (DPP4-Is) for nutritional absorption and intestinal barrier function enhancement. Herein, we investigated the efficacy of DPP4-Is in preventing liver damage in SBS rat models.

Methods

Rats were allocated to one of five groups: normal saline (NS) + sham, DPP4-I + sham, NS + SBS, DPP4-I + SBS, and GLP-2 + SBS. DPP4-I or NS was administered orally once daily. Serum aspartate aminotransferase, alanine aminotransferase (ALT), alkaline phosphatase, and total bile acid levels were measured to assess liver function. Moreover, we evaluated liver damage using the SAF (steatosis activity fibrosis) score, which is also used to assess nonalcoholic steatohepatitis.

Results

ALT levels and SAF scores were significantly lower in the DPP4-I + SBS group than in the NS + SBS group. Jejunal and ileal villus heights were significantly higher in the DPP4-I + SBS group than in the GLP-2 + SBS group.

Conclusions

The downregulation of ALT levels and SAF scores triggered by DPP4-I use may be correlated with DPP4-I-induced adiposis inhibition in SBS and NASH models. Therefore, DPP4-I may be used to reduce IFALD in patients with SBS.

O’Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J (2006) Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 4(1):6–10. https://doi.org/10.1016/j.cgh.2005.10.002CrossRefPubMed

Modi BP, Galloway DP, Gura K, Nucci A, Plogsted S, Tucker A, Wales PW (2022) ASPEN definitions in pediatric intestinal failure. JPEN J Parenter Enteral Nutr 46(1):42–59. https://doi.org/10.1002/jpen.2232CrossRefPubMed

Cavicchi M, Beau P, Crenn P, Degott C, Messing B (2000) Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 132(7):525–532. https://doi.org/10.7326/0003-4819-132-7-200004040-00003CrossRefPubMed

Lacaille F, Gupte G, Colomb V, D’Antiga L, Hartman C, Hojsak I, Kolacek S, Puntis J, Shamir R (2015) Intestinal failure-associated liver disease: a position paper of the ESPGHAN working group of intestinal failure and intestinal transplantation. J Pediatr Gastroenterol Nutr 60(2):272–283. https://doi.org/10.1097/mpg.0000000000000586CrossRefPubMed

Ferguson CL, Perry C, Subramanian M, Gillette C, Ayers K, Welch C (2021) Mixed oil-based lipid emulsions vs soybean oil-based lipid emulsions on incidence and severity of intestinal failure-associated liver disease in a neonatal intensive care unit. JPEN J Parenter Enteral Nutr 45(2):303–308. https://doi.org/10.1002/jpen.1831CrossRefPubMed

Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan H, Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J (2019) Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 69(6):2414–2426. https://doi.org/10.1002/hep.30320CrossRefPubMed

Yano K, Kaji T, Onishi S, Machigashira S, Nagai T, Harumatsu T, Yamada K, Yamada W, Muto M, Nakame K, Mukai M, Ieiri S (2019) Novel effect of glucagon-like peptide-2 for hepatocellular injury in a parenterally fed rat model of short bowel syndrome. Pediatr Surg Int 35(12):1345–1351. https://doi.org/10.1007/s00383-019-04560-8CrossRefPubMed

Sueyoshi R, Ralls MW, Teitelbaum DH (2013) Glucagon-like peptide 2 increases efficacy of distraction enterogenesis. J Surg Res 184(1):365–373. https://doi.org/10.1016/j.jss.2013.03.089CrossRefPubMedPubMedCentral

Lee WS, Chew KS, Ng RT, Kasmi KE, Sokol RJ (2020) Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management. Hepatol Int 14(3):305–316. https://doi.org/10.1007/s12072-020-10048-8CrossRefPubMed

10.

Goulet OJ, Cai W, Seo JM (2020) Lipid emulsion use in pediatric patients requiring long-term parenteral nutrition. JPEN J Parenter Enteral Nutr 44(Suppl 1):S55–S67. https://doi.org/10.1002/jpen.1762CrossRefPubMed

11.

Huff KA, Breckler F, Cruse W, Szeszycki E, Vanderpool C (2021) Pediatric smoflipid therapy: patient response and safety concerns. JPEN J Parenter Enteral Nutr 45(4):792–799. https://doi.org/10.1002/jpen.1929CrossRefPubMed

12.

Sueyoshi R, Miyahara K, Nakazawa-Tanaka N, Fujiwara N, Ochi T, Yamataka A (2020) DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome. Pediatr Surg Int 36(1):49–55. https://doi.org/10.1007/s00383-019-04571-5CrossRefPubMed

13.

Sueyoshi R, Woods Ignatoski KM, Okawada M, Hartmann B, Holst J, Teitelbaum DH (2014) Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model. Am J Physiol Gastrointest Liver Physiol 307(4):G410-419. https://doi.org/10.1152/ajpgi.00363.2013CrossRefPubMed

14.

Okawada M, Holst JJ, Teitelbaum DH (2011) Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery 150(2):217–223. https://doi.org/10.1016/j.surg.2011.05.013CrossRefPubMed

15.

Nakouti T, Karagiannis AK, Tziomalos K, Cholongitas E (2015) Incretin-based antidiabetic agents for the management of non-alcoholic fatty liver disease. Curr Vasc Pharmacol 13(5):649–657. https://doi.org/10.2174/1570161112666141121112612CrossRefPubMed

16.

Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA, Saxena NK, Sorescu D, Anania FA (2012) Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 302(2):G225-235. https://doi.org/10.1152/ajpgi.00274.2011CrossRefPubMed

17.

Naimi RM, Hvistendahl MK, Thomassen LM, Johnsen H, Christiansen CB, Holst JJ, Hartmann B, Jeppesen PB (2021) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterol 8(1):e000604. https://doi.org/10.1136/bmjgast-2021-000604CrossRefPubMedPubMedCentral

18.

Spencer AU, Neaga A, West B, Safran J, Brown P, Btaiche I, Kuzma-O’Reilly B, Teitelbaum DH (2005) Pediatric short bowel syndrome: redefining predictors of success. Ann Surg 242(3):403–409. https://doi.org/10.1097/01.sla.0000179647.24046.03CrossRefPubMedPubMedCentral

Titel: Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition
verfasst von: Ryo Sueyoshi
Nanami Furuhashi
Junya Ishii
Ryusuke Yamaguchi
Marumi Kawakami
Kenji Tanabe
Osamu Segawa
Publikationsdatum: 01.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 1/2023
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-022-05301-0

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition